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Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year 
of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD 
(191 with Crohn’s disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks 
(interquartile range: 103–104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey 
Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 
27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between 
weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes 
compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections 
occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD 
and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 The efficacy and safety of vedolizumab therapy have been 
established in the GEMINI studies and confirmed in real-life 
cohorts up to 1 year.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Long-term real-world data are needed to determine the 
loss of response, dose escalation, and risk of infections beyond 
52 weeks of treatment.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 The effectiveness of vedolizumab therapy between the first 
and second year of follow-up remains fairly stable for patients 
with ulcerative colitis (UC), whereas it decreases over time for 
patients with Crohn’s disease (CD). Concomitant use of im-
munosuppressive medication did not correlate with improved 
effectiveness outcomes but did impose a risk for severe infec-
tions. Dose optimization occurred frequently, also beyond the 
first year of treatment.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Long-term maintenance of clinical remission on vedoli-
zumab seems more feasible for UC than CD, whereas dose op-
timization may aid in improved outcomes. Based on our safety 
data, vedolizumab combination therapy should be carefully 
considered.
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Vedolizumab is a humanized monoclonal IgG-1 antibody inhibiting 
the interaction between the α4β7 integrin and mucosal addressin 
cell adhesion molecule-1. This results in the prevention of lympho-
cyte homing to the inflamed gut tissue. Clinical efficacy of vedoli-
zumab was demonstrated in the GEMINI trials1,2 and vedolizumab 
was subsequently approved for the treatment of Crohn’s disease (CD) 
and ulcerative colitis (UC) in the Netherlands in 2014. Vedolizumab 
is now implemented as biological therapy in daily inflammatory 
bowel disease (IBD) practice. However, patients in the initial phase 
III trials are not representative for the real-life IBD population be-
cause a large proportion of patients in daily practice do not meet the 
predefined inclusion and exclusion criteria.3 Therefore, long-term 
robust real-world effectiveness and safety data are needed.
To date, the effectiveness and safety of vedolizumab in clinical 
practice has been described and confirmed in a number of cohorts 
up to 1 year.4–10 There is, however, only limited data available be-
yond the first year of treatment. Patients from the pivotal phase 
III clinical studies (GEMINI) could be included in the long-term 
open-label studies (GEMINI-LTS) and these trials indicated that 
the effectiveness of vedolizumab remained fairly stable in patients 
who responded to vedolizumab induction.11,12 However, only one 
study presented the safety and effectiveness results beyond 1 year 
in a real-world population.13 In this study, the steroid-free clini-
cal remission rate for UC remained fairly stable beyond the first 
year of treatment, whereas the steroid-free clinical remission rate 
of patients with CD tended to decrease over time. Long-term pro-
spective data on vedolizumab treatment in real-life cohorts is of key 
importance to determine loss of response rates, treatment escala-
tions, and risk of infections and malignancies beyond 52 weeks.
Using the Initiative on Crohn and Colitis (ICC) Registry, a pro-
spective, nationwide, observational registry for novel IBD therapies, 
we aimed to evaluate the real-world effectiveness, safety, and use of 
vedolizumab with a long-term follow-up of 2 years. Furthermore, we 
aimed to determine predictors of clinical remission and to describe 
different treatment strategies used in clinical practice.
METHODS
Study design and setting
The ICC Registry is a nationwide, observational registry with prospec-
tive follow-up of patients with IBD starting prespecified IBD therapies in 
the Netherlands. The design and rationale of the ICC Registry were de-
scribed previously in more detail.14 Briefly, patients with IBD, ≥ 16 years, 
in 8 academic and 4 nonacademic hospitals are followed for 2 years after 
initiating prespecified therapies. Visits are scheduled at initiation of ther-
apy (baseline), week 12, week 24, week 52, and at week 104 or until the 
medication is discontinued. Data collection is done using an electronic 
case report form with automated reminders to improve adherence to the 
protocol. We used the described ICC Registry to document effectiveness 
and safety of vedolizumab therapy for patients with IBD.
Participants
Following formal approval by the regulatory authorities, patients with 
IBD initiating vedolizumab were enrolled in the participating centers. 
Patients  ≥  16  years with an established IBD diagnosis starting vedol-
izumab in regular care were eligible. There were no exclusion criteria. 
The decision to start vedolizumab therapy was at the discretion of the 
treating physician. Patients received vedolizumab therapy i.v. according 
to the label with an induction infusion regimen of 300 mg vedolizumab 
at weeks 0, 2, and 6. In case of insufficient response, an additional vedol-
izumab infusion could be prescribed at week 10 at the discretion of the 
treating physician. The maintenance treatment consisted of 300  mg 
vedolizumab every 8 weeks, whereas the infusion interval could be short-
ened in case of inadequate response. Patients with combined clinical (e.g., 
Harvey Bradshaw Index (HBI) > 4 and Short Clinical Colitis Activity 
Index (SCCAI) > 2) and objective (endoscopy, radiology, or biochemi-
cal: C-reactive protein > 5ml/L and a fecal calprotectin level > 200 µg/g) 
disease activity at baseline were used to determine the effectiveness out-
comes while all enrolled patients, regardless of disease activity scores, 
were used to determine the safety outcomes.
Outcomes and definitions
The primary outcome was the proportion of patients in corticoste-
roid-free clinical remission at week 104. Secondary effectiveness 
outcomes included: clinical response, clinical remission, biochemical 
remission, extra-intestinal manifestations (EIM) remission, vedol-
izumab interval shortening, intestinal surgery, and vedolizumab 
discontinuation rate. Corticosteroid-free clinical remission was com-
pared between CD and UC and between patients on concomitant 
immunosuppressive therapies (thiopurines and methotrexate) and 
without concomitant immunosuppressive medication at baseline. 
Furthermore, predictors for corticosteroid-free clinical remission at 
week 104 were determined. An HBI ≤ 4 and SCCAI ≤ 2 were consid-
ered as clinical remission. A decrease of HBI of SCCAI of ≥ 3 com-
pared with baseline was considered as clinical response.15 Biochemical 
remission was defined as a CRP concentration ≤  5  mg/L combined 
with a fecal calprotectin (FCP) level ≤ 200 µg/g when available for CD 
and only a FCP level of ≤ 200 µg/g for UC. EIM that were collected 
included: arthralgia, arthritis, uveitis, aphthous stomatitis, erythema 
nodosum, and pyoderma gangrenosum. EIM remission was assessed 
by the treating physician. Reason for discontinuation of vedolizumab 
was documented. The safety outcomes were presented as the number 
of medication-related adverse events, infections, and disease-related 
hospitalizations per 100 patient years. Adverse events were classified 
as possibly, probably, and not related. Serious adverse events were clas-
sified as reason for discontinuation of medication. Infections were 
classified as mild (no antibiotics or antiviral medication necessary), 
moderate (oral antibiotics or antiviral medication), or severe (hospi-
talization or i.v. administered antibiotics or antiviral medication).
Follow-up time was determined based on the date of the first dose of 
vedolizumab until the last visit used in the analysis. Patients who discon-
tinued vedolizumab due to primary or secondary nonresponse, adverse 
events, or patient request without long-term sustained remission were 
considered treatment failure and were classified as nonresponders. Patients 
were considered censored cases when they discontinued vedolizumab 
because of pregnancy or long-term sustained remission and were not in-
cluded in the analysis. Because this registry still actively recruits patients, 
only patients with sufficient follow-up time were used in the analysis at 
specific time points. For example, a patient with 70  weeks of follow-up 
contributed to the 52-week analysis, but not to the 104-week analysis, in-
dependent of drug discontinuation.
Statistical methods
Patients were analyzed on an intention-to-treat basis. Continuous vari-
ables were presented as means with standard deviations (SDs) or as me-
dians with interquartile ranges (IQRs) depending on the normality of 
the underlying distribution. Continuous variables were consequently 
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compared using the independent t-test or Mann–Whitney U test. 
Categorical variables were presented as percentages and compared by 
using the χ2 test. The overall drug survival was assessed using the 
Kaplan–Meier method. To compare the drug survival between patients 
with and without interval shortening during maintenance therapy, the 
time-varying Cox regression was used. Variables associated with week 52 
corticosteroid-free clinical remission were explored using binary logistic 
regression. Multivariable analysis was performed on variables with a P 
value < 0.2 on univariable analysis using backward stepwise logistic re-
gression. A twosided P value of 0.05 or less was considered statistically 
significant. All data analyses were performed using IBM SPSS Statistics 
for Windows, version 24.0 (IBM, Armonk, NY).
Ethical consideration
This study was reviewed and approved by the Committee on Research 
Involving Human Subjects at the Radboudumc (institutional review 
board: 4076).
RESULTS
Baseline characteristics
Baseline characteristics are depicted in Table  1. In total, 310 
patients with IBD were included: 191 patients with CD, 113 
patients with UC, and 6 patients with IBD-Unclassified (IBD-
U). The results of the patients with IBD-U are presented with 
the results of the patients with UC due to the limited number of 
patients with IBD-U. The 191 patients with CD were followed 
with a median follow-up period of 104.0 weeks (IQR: 104.0–
104.0). The patients with CD were predominately women 
(n = 122; 63.9%) with a median disease duration of 11.0 years 
(IQR: 6.4–19.7). At inclusion, an ileocolonic disease location 
was observed in 40.8% (n  =  78), whereas 12.0% (n  =  23) had 
a penetrating disease phenotype, and 12.0% (n = 23) had peri-
anal disease activity at maximum extent and behavior during 
their disease course. The majority of patients (95.9%) were pre-
viously exposed to thiopurines or methotrexate, 188 patients 
(98.4%) were exposed to at least 1 anti-TNF agent, and 148 
patients (77.5%) to 2 or more anti-TNF agents. Eleven patients 
(5.8%) were previously exposed to ustekinumab. A history of 
intestinal resections was documented in 97 patients (50.8%).
In the UC cohort, 113 patients with UC and 6 patients 
with IBD-U were followed with a median follow-up period of 
104.0  weeks (IQR: 96.9–104.0  weeks). The patients with UC 
were predominately men (n = 66; 55.5%) with a median disease 
duration of 7.8 years (IQR: 2.8–14.9). Pancolitis was seen in 48.7% 
(n = 58) at inclusion. The majority of patients (92.7%) were previ-
ously exposed to thiopurines or methotrexate and 104 (87.4%) had 
failed at least 1 anti-TNF agent, whereas 44 (36.9%) had failed 2 or 
more anti-TNF agents.
At baseline, combined clinical and objective disease activity 
was determined in 138 patients with CD with a median HBI of 
9 (IQR: 6–12) and 94 patients with UC with a median SCCAI 
of 7 (IQR: 4–9). Of the 53 patients with CD and 25 patients 
with UC without both clinical and objective disease activity 
at baseline, 92.5% (n  =  49/53) and 84.0% (n  =  21/25) of pa-
tients had disease activity based on clinical disease activity, ac-
tive draining fistula, inflammatory biomarkers, endoscopy, or 
radiology. These patients were not included in the effectiveness 
analyses.
Corticosteroid-free clinical remission
For CD, the proportion of patients in corticosteroid-free clinical 
remission at weeks 12, 24, 52, and 104 was 24.3% (n = 33/136), 
30.6% (n = 41/134), 27.7% (n = 36/130), and 19.0% (n = 24/126), 
respectively (Figure 1). Of the 36 patients in corticosteroid-free 
clinical remission at week 52, 55.6% remained in corticoste-
roid-free clinical remission up to week 104. When analyzing 
all patients, including the 63 patients without both clinical and 
objective disease activity at baseline, the corticosteroid-free clin-
ical remission rate at weeks 0, 12, 24, 52, and 104 was 13.6% 
(n  =  26/191), 30.3% (n  =  57/188), 34.2% (n  =  63/184), 28.3% 
(n = 51/180), and 22.5% (n = 39/173), respectively.
For UC, the proportion of patients in corticosteroid-free 
clinical remission at weeks 12, 24, 52, and 104 was 29.0% 
(n = 27/93), 34.4% (n = 32/93), 27.3% (n = 24/88), and 27.7% 
(n = 23/83), respectively (Figure 1). Of the 24 patients in cor-
ticosteroid-free clinical remission at week 52, 60.9% remained 
in corticosteroid-free clinical remission up to week 104. When 
analyzing all patients, including the 26 patients in clinical remis-
sion at baseline, the corticosteroid-free clinical remission rate 
at weeks 0, 12, 24, 52, and 104 was 8.4% (n = 10/119), 32.5% 
(n  =  38/117), 36.2% (n  =  42/116), 29.6% (n  =  32/108), and 
26.5% (n = 27/102), respectively.
Coadministration of immunosuppressive therapy (thiopurines 
or methotrexate, combination therapy) was documented in 82 pa-
tients with IBD (35.3%) with clinical and objective disease activ-
ity at baseline. When the latter group was compared with patients 
who received vedolizumab monotherapy, baseline characteristics, 
including clinical and biochemical disease activity, except CRP 
(monotherapy: 8  mg/L (IQR: 4–23) vs. combination therapy: 
5  mg/L (IQR: 2–14), P  =  0.02), were comparable between the 
subgroups. The proportion of patients in corticosteroid-free clin-
ical remission was 26.5% (monotherapy) vs. 25.6% (combination 
therapy) P = 0.88 at week 12, 32.4% vs. 31.7% P = 0.91 at week 
24, 26.2% vs. 29.1% P  =  0.65 at week 52, and 22.8% vs. 21.1% 
P = 0.77 at week 104 (Figure 2).
Clinical response and remission
For CD, the proportion of patients with a clinical response to 
vedolizumab therapy at weeks 12, 24, 52, and 104 was 49.3% 
(n = 67/136), 40.3% (n = 54/134), 28.5% (n = 37/130), and 22.2% 
(n = 28/129), respectively. The proportion of patients in clinical 
remission at weeks 12, 24, 52, and 104 was 34.6% (n = 47/136), 
35.1% (n = 47/134), 30.0% (n = 39/130), and 19.8% (n = 25/126), 
respectively (Figure 1).
For UC, the proportion of patients with a clinical response 
to vedolizumab therapy at weeks 12, 24, 52, and 104 was 50.5% 
(n = 47/93), 41.9% (n = 39/93), 35.2% (n = 31/88), and 28.9% 
(n  =  24/83), respectively. The proportion of patients in clinical 
remission at weeks 12, 24, 52, and 104 was 36.6% (n  =  34/93), 
36.6% (n = 34/93), 28.4% (n = 25/88), and 27.7% (n = 23/83), 
respectively (Figure 1).
Biochemical disease activity
For CD, the proportion of patients in biochemical remission 
at weeks 12, 24, 52, and 104 was 24.4% (n  =  31/127), 33.1% 
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(n  =  40/121), 22.4% (n  =  28/125), and 17.8% (n  =  21/118), re-
spectively (Figure 3a). When missing data was imputed as nonre-
sponder, the proportion of patients in biochemical remission was 
22.8% (n = 31/136), 29.9% (n = 40/134), 21.2% (n = 28/132), and 
16.3% (n  =  21/129), respectively. The median CRP concentra-
tion of patients treated with vedolizumab at weeks 0, 12, 24, 52, 
and 104 was 8 mg/L (IQR: 4–23), 8 mg/L (IQR: 3–14), 5 mg/L 
(IQR: 2–11), 5  mg/L (IQR: 3–11), and 5  mg/L (IQR: 2–10), 
Table 1 Baseline characteristics
    CD N = 191 UC N = 119
Agea Median (IQR) 36.8 (27.0–52.5) 40.4 (30.2–55.5)
Sex – male N (%) 69 (36.1) 66 (55.5)
Body mass indexa Mean (SD) 23.8 (4.2) 24.4 (4.7)
Current smoker N (%) 46 (24.1) 4 (3.4)
Disease duration in years Median (IQR) 11.0 (6.4–19.7) 7.8 (2.8–14.9)
Follow-up duration Median (IQR) 104.0 (104.0–104.0) 104.0 (96.9–104.0)
CD disease locationa 
Ileum N (%) 57 (29.8)  
Colon N (%) 56 (29.3)  
Ileum and colon N (%) 78 (40.8)  
Upper GI involvement N (%) 19 (9.9)  
UC disease location
Proctitis N (%)   8 (6.7)
Left-sided N (%)   49 (41.2)
Pancolitis N (%)   58 (48.7)
Unknown N (%)   4 (3.4)
Disease behaviora 
Inflammatory disease N (%) 115 (60.2)  
Stricturing disease N (%) 50 (26.2)  
Penetrating disease N (%) 23 (12.0)  
Unknown N (%) 3 (1.6)  
Peri-anal diseasea N (%) 23 (12.0)  
Prior intestinal resections N (%) 97 (50.8)  
Prior peri-anal interventions N (%) 34 (17.8)  
Prior anti-TNF therapy use
≥ 1 N (%) 188 (98.4) 104 (87.4)
≥ 2 N (%) 148 (77.5) 44 (36.9)
3 N (%) 8 (4.2) 6 (5.0)
Prior ustekinumab use N (%) 11 (5.8)  
Prior anti-integrin trial participation N (%) 7 (3.7) 1 (0.8)
Disease activitya 
HBI/SCCAI Median (IQR) 7 (5–11) 6 (3–9)
CRP, mg/L Median (IQR) 7 (3–19) 4 (1–12)
Fecal calprotectin, µg/g Median (IQR) 689 (297–1800) 1317 (527–2013)
Concomitant medication
No concomitant medication N (%) 72 (37.7) 41 (34.5)
Corticosteroids N (%) 55 (28.8) 33 (27.7)
Corticosteroids range mg (IQR) 25 (20–40) 25 (18–40)
Immunosuppressants N (%) 39 (20.4) 20 (16.8)
Both corticosteroids and 
immunosuppressants
N (%) 25 (13.1) 25 (21.0)
Corticosteroids range mg (IQR) 20 (15–30) 30 (20–40)
CD, Crohn’s disease; HBI, Harvey Bradshaw Index; GI, gastrointestinal; IQR, interquartile range; SCCAI, short clinical colitis activity index; UC, ulcerative colitis.
aAt inclusion. bMaximum extent until inclusion.
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respectively. The median FCP level at weeks 0, 12, 24, 52, and 
104 was 817 µg/g (IQR: 352–1800), 425 µg/g (IQR: 193–1,307), 
160 µg/g (IQR: 54–755), 142 µg/g (IQR: 49–653), and 96 µg/g 
(IQR: 25–250), respectively.
For UC, the proportion of patients in biochemical remis-
sion at weeks 12, 24, 52, and 104 was 24.2% (n = 16/66), 32.9% 
(n = 26/79), 28.2% (n = 20/71), and 20.6% (n = 14/68), respec-
tively (Figure  3b). When missing data were imputed as nonre-
sponder, the proportion of patients in biochemical remission was 
17.2% (n = 16/93), 28.0% (n = 26/93), 22.7% (n = 20/88), and 
16.9% (n  =  14/83), respectively. The median CRP concentra-
tion of patients treated with vedolizumab at weeks 0, 12, 24, 52, 
and 104 was 6 mg/L (IQR: 2–13), 4 mg/L (IQR: 1–7), 3 mg/L 
(IQR: 1–6), 3 mg/L (IQR: 1–6), and 3 mg/L (IQR: 1–6), respec-
tively. The median FCP level at weeks 0, 12, 24, 52, and 104 was 
1,317 µg/g (IQR: 588–2,004), 319 µg/g (IQR: 58–1,551), 85 µg/g 
(IQR: 10–510), 75 µg/g (IQR: 0–223), and 30 µg/g (IQR: 0–97), 
respectively.
Combined end point
The proportion of patients with CD in combined corticoste-
roid-free clinical and biochemical remission at weeks 12, 24, 52, 
and 104 was 10.2% (n  =  13/127), 18.2% (n  =  22/121), 13.6% 
(n = 17/125), and 11.9% (n = 14/118), respectively.
The proportion of patients with UC in combined cortico-
steroid-free clinical and biochemical remission at weeks 12, 24, 
Figure 1 Clinical response, clinical remission, and corticosteroid-free clinical remission for patients with Crohn's disease and patients with 
ulcerative colitis.
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52, and 104 was 16.7% (n = 11/66), 24.1% (n = 19/79), 18.3% 
(n = 13/71), and 14.7% (n = 10/68), respectively.
Clinical factors associated with corticosteroid-free clinical 
remission
Univariable and multivariable predictors of corticosteroid-free clin-
ical remission at week 104 are displayed in Table 2. There were no 
clinical or biochemical parameters predictive of corticosteroid-free 
clinical remission at week 104 in the multivariable analysis.
EIMs
At baseline, 32 patients with CD (16.8%) experienced active 
EIM: 29 patients reported arthralgia, 1 uveitis, 1 aphthous 
stomatitis, and 1 pyoderma gangrenosum. During the 2-year 
follow-up period, EIM remission was achieved in 13 patients 
(44.8%) with arthralgia, and all patients with uveitis (100%), 
aphthous stomatitis (100%), and pyoderma gangrenosum 
(100%). All but four patients with arthralgia were in clinical CD 
remission when EIM remission was achieved. During follow-up, 
a total of 33 patients CD (17.3%; 28 patients with clinical dis-
ease activity) developed new EIM: 22 patients developed ar-
thralgia, 2 uveitis, 6 aphthous stomatitis, 1 erythema nodosum, 
and 2 pyoderma gangrenosum. Of the newly developed EIMs, 6 
arthralgia (25%), 2 uveitis (100%), 0 aphthous stomatitis (0%), 
0 erythema nodosum (0%), and 0 pyoderma gangrenosum (0%), 
achieved remission during follow-up.
Of all 119 patients with UC, 10 (8.4%) experienced EIM: 7 
arthritis, 2 uveitis, and 1 pyoderma gangrenosum. During the en-
tire follow-up, four patients (57.1%) with arthritis and one (50%) 
patient with uveitis achieved remission. All but one patient with 
uveitis were in clinical UC remission when EIM remission was 
achieved. During follow-up, a total of 21 patients with UC (17.6%; 
13 patients with clinical disease activity) developed new EIMs: 13 
arthritis, 4 uveitis, 2 aphthous stomatitis, and 2 erythema nodo-
sum. Of the newly developed EIMs, 3 arthritis (37.5%), 2 uveitis 
(50%), 0 aphthous stomatitis (0%), and 0 erythema nodosum (0%) 
achieved remission during follow-up.
Safety profile
The 310 patients included in our safety analysis were followed for 
347.2 patient years and received in total 2,760 infusions. Ten pa-
tients (2.9 per 100 patient years) discontinued due to adverse events, 
including arthralgia (n = 4), infusion reactions (n = 2), infusion-re-
lated adverse events (n = 2), headache (n = 1), and gastrointestinal 
infection (n = 1; Table 3). During follow-up, we encountered 20 (5.8 
per 100 patient years) probably related and 73 (21.0 per 100 patient 
years) possibly related adverse events. The most common adverse 
events were cutaneous lesions, infusion-related adverse events, and 
Figure 2 Corticosteroid-free clinical remission of vedolizumab (VDZ) monotherapy vs. vedolizumab combination therapy (Combination therapy: 
vedolizumab therapy with an immunosuppressant (thiopurines or methotrexate)).
Figure 3 Biochemical remission (C-reactive protein ≤ 5 mg/L, fecal calprotectin ≤ 200 µg/g) for patients with Crohn's disease (CD) and (fecal 
calprotectin ≤ 200 µg/g) for patients with ulcerative colitis (UC).
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arthralgia. Additionally, we documented 13 severe infections (3.7 
per 100 patient years), 8 of these happened when the patient was on 
concomitant immunosuppressive therapies (thiopurines, cortico-
steroids, or both). Forty-two (12.1 per 100 patient years) moderate 
infections and 78 (22.5 per 100 patient years) mild infections were 
documented. Most common infections affected the respiratory and 
gastrointestinal tracts. During follow-up, two cases of malignan-
cies were diagnosed and one progressed. Two patients discontinued 
vedolizumab therapy due to a malignancy (1 peritonitis carcinoma-
tosa originating from the digestive tract and 1 progression of anaplas-
tic oligodendroglioma). One 71-year-old patient developed prostate 
cancer with lymphoid metastasis but continued vedolizumab treat-
ment. One patient died during follow-up: a 51-year-old male patient 
with UC died due to a thrombosis in the basilar artery during vedol-
izumab treatment. In total, 84 (24.2 per 100 patient years) hospi-
talizations occurred during follow-up. Fourteen patients with CD 
(7.3%) and 8 patients with UC (7.1%) required intestinal (sub)total 
colectomy.
Optimization of vedolizumab therapy
Of the 310 patients included in our cohort, 46 patients (14.8%) 
discontinued vedolizumab therapy before the fourth infusion 
(week 10 or 14). The extra induction infusion around week 
10 was given to 34.5% (n  =  107/310; CD: 47%, n  =  89/191; 
UC: 15.1%, n = 18/119) of patients. During maintenance ther-
apy, 23.1% (n  =  61/264; CD: 45; UC: 16) received interval 
Table 2 Univariable and multivariable predictors for corticosteroid free remission at week 104
 
Univariable analyses Multivariable analyses
OR 95% CI P value OR 95% CI P value
Age at inclusion 1.00 0.98–1.02 0.93      
BMI per pointa 1.01 0.92–1.10 0.91      
Sex
Male ref          
Female 0.95 0.49–1.84 0.88      
Disease duration 0.99 0.95–1.02 0.46      
Disease location CDa     0.16     0.25
Ileum ref     ref    
Colon 1.80 0.48–6.74 0.38 0.95 0.22–4.08 0.94
Ileocolonic 3.16 0.94–10.65 0.06 2.12 0.59–7.65 0.25
Disease location UC     0.90      
Proctitis Ref          
Left-sided 1.50 0.14–16.14 0.74      
Pancolitis 1.03 0.10–10.97 0.98      
Upper GI involvementa            
No ref          
Yes 0.27 0.03–2.19 0.22      
Disease behaviora     0.29      
Inflammatory disease ref          
Stricturing disease 0.25 0.05–1.17 0.08      
Penetrating disease 1.36 0.42–4.35 0.61      
Peri-anal disease            
No ref          
Yes 1.01 0.99–1.03 0.37      
Prior intestinal resections            
No ref     ref    
Yes 0.31 0.13–0.73 <0.01 0.35 0.12–1.01 0.05
Biochemical disease activitya            
CRP per mg/L 0.99 0.96–1.01 0.15      
Concomitant medicationa            
Corticosteroids 0.86 0.45–1.65 0.65      
Immunosuppressant 0.88 0.44–1.74 0.88      
Clinical parameters associated with corticosteroid-free clinical remission at week 52 (BMI, GI, and CRP).
BMI, body mass index; CD, Crohn’s disease; CI, confidence interval; GI, gastrointestinal; OR, odds ratio; UC, ulcerative colitis.
aAt inclusion. bMaximum extent until inclusion.
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shortening (interval of ≤ 6 weeks) after a median treatment du-
ration of 30.0  weeks (IQR: 14.1–48.6) for patients with CD 
and 46.1  weeks (IQR: 22.0–65.4) for patients with UC. The 
median duration between interval shortening and last visit or 
until treatment discontinuation was 30.0  weeks (IQR: 4.8–
74.2) for patients with CD and 50.6 weeks (IQR: 24.6–62.8) 
for patients with UC. There was no significant difference in 
drug survival rate between patients on 8-week infusions vs. pa-
tients who underwent interval shortening (hazard ratio: 1.18; 
95% confidence interval (CI): 0.71–1.95).
Drug survival
Cumulative vedolizumab drug survival is demonstrated in 
Figure 4. Of 310 patients, 162 patients (52.3%; CD: 109; 57.1%; 
UC: 53 44.5%) discontinued vedolizumab treatment after a me-
dian treatment duration of 27.4 weeks (IQR: 17.2–51.8) for CD 
and 18.9 weeks (IQR: 11.8–40.9) for UC (Table 4). Main reasons 
for discontinuing treatment were: lack of response (CD: 61.5%; 
UC: 81.1%), loss of response (CD: 18.3%; UC: 9.4%), and adverse 
events (CD: 7.3%; UC: 3.8%). Five patients with CD discontin-
ued vedolizumab treatment due to pregnancy. The probability 
of continuing receiving vedolizumab treatment after 52 and 
104 weeks was 54.0% and 38.4% for CD and 60.8% and 51.3% 
for UC, respectively.
DISCUSSION
In this real-world prospective cohort of anti-TNF exposed vedol-
izumab treated patients with IBD, the corticosteroid-free clinical 
remission rate at week 104 was 19% for patients with CD and 28% 
for UC. Of the patients who were in corticosteroid-free clinical 
Table 3 Adverse events
Possibly related   73 (21.0 per 100 
patient-years)
Cutaneous lesions 23  
Infusion related 10  
Arthralgia 6  
Headache 8  
Respiratory 3  
Other 3  
GI 2  
Exacerbation IBD 2  
Cardiac event 2  
Kidney/urinary tract 2  
Dizziness 2  
Malignancy 2  
Psychiatric 2  
Vascular 2  
Eye condition 1  
Fatigue 1  
Itch 1  
Transient tingling sensation 1  
Probably related   20 (5.8 per 100 
patient-years)
Infusion related 8  
Cutaneous lesions 5  
Arthralgia 2  
Nervous system 2  
Headache 1  
Dizziness 1  
Muscle cramp 1  
Serious adverse events   10 (2.9 per 100 
patient-years)
Arthralgia 4  
Infusion reaction 2  
Infusion related 2  
Headache 1  
GI infection 1  
Mild infections   78 (22.5 per 100 
patient-years)
Upper respiratory 38  
Flu-like syndrome 16  
GI 10  
Fever (no focus) 7  
Cutaneous lesions 3  
Herpes zoster 2  
Soft tissue 1  
Cold sore 1  
Moderate infections   42 (12.1 per 100 
patient-years)
Upper respiratory 15  
 (Continued)
GI 6  
Other 5  
Urinary tract 4  
Cutaneous lesions 3  
Pneumonia 3  
Herpes zoster 2  
Eye infection 1  
Gynecological 1  
Fever (no focus) 1  
Jaw/teeth 1  
Severe infections   13 (3.7 per 100 
patient-years)
GI 5  
Pneumonia 5  
Upper respiratory 1  
Other 1  
Musculoskeletal inflammation 1  
Adverse events during vedolizumab treatment (mild: no antibiotics or 
antiviral medication, moderate: oral antibiotics or antiviral medication, 
severe: hospitalization or intravenously administrated antibiotics or antiviral 
medication).
GI, gastrointestinal; IBD, inflammatory bowel disease.
Table 3 (Continued)
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remission at week 52, 59% remained in corticosteroid-free clinical 
remission up to week 104. A relatively large proportion of patients 
received an additional dose on week 10 (35%) or dose escalation 
during maintenance therapy (23%). No new safety signals were 
observed, whereas the majority of severe infections (3.7 per 100 
patients years) were seen in patients receiving concomitant treat-
ment with immunosuppressive agents.
Here, we report the 104-week corticosteroid-free clinical remis-
sion rate in patients with IBD treated with vedolizumab. There 
is only one other study with this duration of follow-up showing 
comparable results (week 108: CD: 24%, UC: 33%).13 Other 
available real-life cohort studies used follow-up periods up to 
1 year. Here, we show corticosteroid-free clinical remission rates of 
28% for patients with CD and 27% for patients with UC at week 
52. Differences in effectiveness rates between real-world cohorts 
could, at least partly, be explained by the methods of analyzing pa-
tients who discontinued vedolizumab. Stallmach et al.6 (corticoste-
roid-free clinical remission: 15% CD, 22% UC), the VICTORY 
consortium UC (corticosteroid-free clinical remission: 37%, non-
response imputation: 15%) used nonresponder imputation and 
intention-to-treat analysis comparable to our study. This conser-
vative approach harbors the risk of underestimating treatment ef-
fect, but seems to be more appropriate for shared decision making 
in daily practice. Other cohorts excluded primary nonresponders 
before week 14 (GETAID, week 54 corticosteroid-free clinical 
remission: 27% CD, 41% UC16), or only included in the effective-
ness analysis a selection of patients who continued vedolizumab 
therapy after 52 weeks (corticosteroid-free clinical remission: 54% 
CD, 59% UC8). The US VICTORY consortium for CD used the 
Kaplan–Meier method and reported cumulative rates of clinical 
remission of 35%. This method generally overestimates treatment 
effects as it ignores subjects who have discontinued treatment and 
does not consider loss of remission after initial response.17 Thus, 
clinical effectiveness at week 54 varies between 15% and 59% and 
differences in methodology, cohorts, and statistical analyses do not 
allow for a detailed comparison of corticosteroid-free clinical re-
mission rates.
Data on clinical benefit after 2 years of vedolizumab treatment 
and drug survival beyond the first year of treatment is scarce, but 
important for daily clinical practice. Due to the low rate of an-
ti-vedolizumab antibodies seen in clinical trials and observational 
cohorts (0–3% persistent positive1,2,18,19), loss of response due to 
immunogenicity would be expected to be lower in vedolizum-
ab-treated patients compared with patients on anti-TNF beyond 
the first year of therapy. Although the probability of continuing 
vedolizumab treatment decreased from 54% to 38% in patients 
with CD between the first and second year after treatment initia-
tion, this probability remained fairly stable for UC (61% to 51%). 
The clinical benefit was maintained in 56% of patients with CD 
and 61% of patients with UC. These vedolizumab drug survival 
rates are comparable or possibly even better when compared with 
historic data on anti-TNF treatment (13% discontinuation rate 
for both infliximab and adalimumab every year after the first year 
in CD20). However, clinical effect is not always maintained when 
remission is achieved. Additional real-life cohorts with long-term 
follow-up are needed to assess and confirm these observations.
We assessed in exploratory analyses the impact of cotreatment 
with immunosuppressive medication (thiopurines and methotrex-
ate) on clinical outcomes during vedolizumab treatment. Although 
this population was not randomized and these analyses may be at 
risk for selection bias, baseline characteristics were comparable 
between the subgroups. The comparable outcomes at week 104 
(corticosteroid-free clinical remission: vedolizumab monother-
apy 23% vs. combination therapy 21% P = 0.77) suggest no clear 
clinical benefit of additional immunosuppressive therapy. From a 
Figure 4 Cumulative drug survival. CD, Crohn's disease; UC, 
ulcerative colitis.
Table 4 Discontinuation visit
 
CD
N = 109 (57.1%)
UC
N = 53 (44.5%)
Treatment duration – weeks Median (IQR) 27.4 (17.2–51.8) 18.9 (11.8–40.9)
Reason discontinuation
No response N (%) 67 (61.5) 43 (81.1)
Loss of response N (%) 20 (18.3) 5 (9.4)
Adverse events N (%) 8 (7.3) 2 (3.8)
Malignancy N (%) 2 (1.8)  
Pregnancy N (%) 5 (4.6)  
Request patient N (%) 5 (4.6) 1 (1.9)
Unknown N (%) 2 (1.8) 2 (3.8)
CD, Crohn’s disease; IQR, interquartile range; UC, ulcerative colitis.
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safety perspective, 8 of 13 severe infections occurred in patients on 
combination therapy, suggesting that vedolizumab in patients with 
IBD might preferably be initiated as monotherapy.
A beneficial effect of vedolizumab treatment on EIM was seen 
in 21 of 42 patients (50%) who reported EIM at baseline, which 
is in line with the OBSERV-IBD study.21 Although 21 patients 
achieved EIM remission in the present study, 54 patients devel-
oped EIM during follow-up. Twelve of these EIMs (7 arthralgia, 2 
uveitis, 2 aphthous stomatitis, and 1 arthritis) developed in patients 
who were in clinical remission. Only 2 of 12 patient (aphthous sto-
matitis and uveitis) were simultaneously in biochemical remission, 
however endoscopic disease activity was not ruled out. Due to the 
gut-specific mechanism of action of vedolizumab, tapering of cor-
ticosteroids during the first months of vedolizumab treatment, and 
the relatively low probability of response to treatment (week 24: 
CD 40%, UC: 42%), insufficient anti-inflammatory treatment of 
these specific patients with IBD may explain the development of 
new EIMs.
The safety profile of vedolizumab therapy observed in our study 
was similar to earlier studies (GEMINI trials and real-world co-
horts).1,2,11,12,22 The incidence of serious adverse events and severe 
infections was relatively low with 2.9 and 3.7 per 100 patient years, 
respectively. The most commonly reported infections in the cur-
rent study were related to the gastrointestinal and respiratory tracts. 
One death occurred during follow-up due to a basilar thrombosis 
in a male patient with UC with a disease duration of 5 years and 
with a history of atherosclerosis. Although we observed three ma-
lignancies, at least two and possibly all three were preexistent. The 
relatively low rate of serious adverse events, including thrombotic 
events and new malignancies, underscores the favorable safety pro-
file of vedolizumab, but also underlines the importance to continue 
monitoring of long-term safety outcomes in patients with IBD.
An additional week 10 infusion and interval shortening during 
maintenance therapy was frequently observed in our cohort (week 
10 and optimization during maintenance treatment: 35% and 23%, 
respectively). Although an additional week 10 infusion is only sug-
gested for patients with CD , according to the label and guidelines, 
a substantial proportion of patients with UC received this extra 
infusion (15.1%). The median treatment duration until interval 
shortening during maintenance treatment and between interval 
shortening and discontinuation or end of follow-up, suggests that 
patients with an initial response to vedolizumab treatment may 
benefit from interval shortening following loss of response. This 
is in line with earlier work that reported loss of response rates of 
47.9 (95% CI: 26.3–87.0) and 39.8 (95% CI: 35.0–45.3) per 100 
person-years with a 53.8% efficacy rate of dose intensification in 
secondary nonresponders.23 The latter and our results suggest that 
interval shortening may be a useful approach in secondary nonre-
sponders in order to regain clinical effect.
Our study has several strengths. The systematic prospective fol-
low-up with a substantial cohort size, nationwide coverage, and 
long follow-up period enabled us to create a representative cohort 
that reflects daily care. The characteristics of our cohort (anti-TNF 
experienced) and intention-to-treat analyses of all patients initi-
ating vedolizumab treatment allowed us to document clinically 
relevant effectiveness and safety outcomes useful for everyday 
practice. Our study also has some limitations. An important lim-
itation lies in the lack of systematic information regarding muco-
sal healing. Because endoscopic evaluation was not mandatory in 
our design, not all centers performed endoscopy systematically or 
at predefined time points. Endoscopy was often performed when 
noninvasive markers were inconclusive, thereby creating selection 
bias when presenting these data. Furthermore, trough levels and 
anti-vedolizumab antibodies were not available for all patients, 
limiting the interpretation of the relevance and effectiveness of 
nonresponse and dose escalation.
In conclusion, 19% (CD) and 28% (UC) of anti-TNF exposed 
patients with IBD treated with vedolizumab were in corticoste-
roid-free clinical remission after 2 years. Fifty-nine percent of pa-
tients with IBD who were in corticosteroid-free clinical remission 
at week 52 maintained corticosteroid-free clinical remission up 
to 2 years. No new safety signals for vedolizumab treatment were 
found, whereas concomitant use of immunosuppressive therapy 
was associated with an increased risk of severe infections with-
out an additional clinical benefit compared with vedolizumab 
monotherapy.
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